NASDAQ:IRWD

Ironwood Pharmaceuticals Q3 2025 Earnings Results & Report

Ironwood Pharmaceuticals logo
$4.68 -0.10 (-2.11%)
As of 02:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ironwood Pharmaceuticals beat analyst expectations on both earnings and revenue in its Q3 2025 results, released November 10, 2025. The company reported EPS of $0.24 versus the $0.09 consensus estimate, while revenue of $122.06 million topped the $74.22 million estimate by $47.84 million.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
7:00 AM ET

Ironwood Pharmaceuticals EPS Results

Actual EPS
$0.24
Consensus EPS
$0.09
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Ironwood Pharmaceuticals Revenue Results

Actual Revenue
$122.06 million
Expected Revenue
$74.22 million
Beat/Miss
Beat by +$47.84 million
YoY Revenue Growth
N/A

Ironwood Pharmaceuticals Q3 2025 Earnings FAQ

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported earnings of $0.24 per share for Q3 2025, beating the consensus estimate of $0.09. The report was announced on Monday, November 10, 2025.

Ironwood Pharmaceuticals reported revenue of $122.06 million for Q3 2025, against a consensus estimate of $74.22 million.

Ironwood Pharmaceuticals Earnings Headlines

Ironwood Pharmaceuticals Earnings Call Signals Strong 2026 Momentum
A Bill Would Reprice America's Gold at Market Value
The US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.tc pixel
Ironwood (IRWD) Q3 2026 Earnings Call Transcript
See More Ironwood Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ironwood Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ironwood Pharmaceuticals and other key companies, straight to your email.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ:IRWD) is a biotechnology company focused on developing and commercializing treatments for gastrointestinal diseases. Founded in 1998, the company is headquartered in Boston, Massachusetts.

Its principal product is LINZESS (linaclotide), a prescription medicine for adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. Ironwood and AbbVie collaborate on the product’s U.S. commercialization, while licensing partners make linaclotide available in other markets under regional brand names.

Ironwood has also expanded its research and development efforts in gastrointestinal and rare diseases. Its pipeline includes apraglutide, an investigational treatment for short bowel syndrome with intestinal failure, which it obtained through its acquisition of VectivBio.

View Ironwood Pharmaceuticals Profile